- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Berlin-based Nanotechnology Company fulfills revenue expectations.
The Berlin-based Capsulution Nanoscience AG fulfilled its turnover expectations
in 2006 with more than 1.3 million euro. In comparison to the year before,
the developer of nanotechnological „active component packages‰ managed with
this an increase of about 50 %. The personnel figures rose to a final 20
members of staff, more than half of which are highly-qualified scientists
and laboratory staff in the field of research and development.
As well as carrying out numerous customer projects, Capsulution has
undertaken vital steps to test its own technology in preclinical studies and
adapt to the requirements of industrial customers, evident in its
collaboration with the Charité, started at the end of 2006. Due to such
preliminary developments, the EBIT margin with about TEUR -150 still turned
out negatively. "With this operational result, our company is clearly faring
better than many other start-up technology companies in the same field,"
states Alexander Herrmann, CFO.
Herrmann is optimistic about the year to come: " Our aim is not only to
increase the turnover to double figures but also to break even." These high
expectations are based not in the least on the positive developments of the
past months. Since November, Capsulution has, with the additional granting
of its basis patent for its LBL Technology yet another competitive edge on
Speaking for the good growth prognoses are further well-known partner and
customer acquisitions with commissioned developments in innovative
nanoproducts forged in the last year, such as the published developments
with the Schering AG (today Bayer Schering Pharma AG) or the Eyesense AG.
About Capsulution Nanoscience AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on
the development of tailor-made drug delivery systems and other innovative
life science products based on tunable nano-sized capsules. The company
applies its worldwide-patented so-called LBL-Technology®. Based on their
minute size, their functionality and their highly reproducible production
process the tunable capsules can be used for a multitude of different
applications. Accordingly, the precisely sized capsules can be made to
function in a manner to suit the intended application, and can be given the
appropriate biochemical, electrical, optical and magnetic properties as
required by the customer. In order to meet customers needs for complete
product solutions Capsulution has recently designated EBARA Corp. as the
preferred developer, manufacturer and distributor for automated LBL-units.
Only six month after the signing of the licence agreement, EBARA has started
operation of the first prototype plant (LBL-Unit®) for the manufacture of
Capsulution's LBL capsules.
For more information, please click here
Herr Dipl.-Kfm. Alexander Herrmann
Phone: +49 (0)30-670 6919-0
Fax: +49 (0)30-670 69 19-101
Copyright © Capsulution NanoScience AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017